What Virchow Biotech does

Virchow Biotech Private Limited (VBPL) is an India-based biopharmaceutical manufacturer that develops, produces, and commercializes biogenerics, biosimilars, active pharmaceutical ingredients (APIs), medical devices, and finished dosage formulations across therapeutic areas including advanced wound care, orthopedics, oncology, hematology, gastroenterology, cardiology, ophthalmology, critical care, neurology, endocrinology, nutraceuticals, and equine blood products. Incorporated in 2001 in Hyderabad as a subsidiary of The Virchow Group, with R&D roots tracing to 1999 at Vanderbilt University, VBPL operates five manufacturing units across Hyderabad and Sangareddy (including a dedicated Medical Device Park facility) and serves pharmaceutical distributors, healthcare providers, hospitals, and contract manufacturing clients in over 100 countries, with a regional office in the United States. The company's portfolio is anchored by pioneering biogenerics such as HEALACE (recombinant PDGF-BB gel for diabetic foot ulcers), OSTEOTIDE (teriparatide for osteoporosis), plasma-derived V-Immune and V-Alb, and Rasburicase, complemented by hyaluronic acid viscosupplements and anticoagulants.

VBPL's business model combines direct B2B enterprise sales of branded biopharmaceutical products, third-party contract manufacturing services for tablets, injections, and new drugs, and co-development/licensing partnerships with international pharma companies. Pricing is quote-based for institutional and enterprise customers and is not publicly disclosed. Revenue mechanics span one-time product sales, professional services for CMO engagements, and licensing/royalty arrangements from co-development. The company reinvests nearly 10% of turnover into R&D and holds a multi-jurisdictional regulatory footprint including USFDA, WHO-GMP, DCGI, ANVISA, INVIMA, PICS, NNHPD, and ISO 13485:2016, which collectively function as the primary barrier to entry supporting its export-led model.

Name

Virchow Biotech

Legal name

VIRCHOW BIOTECH PRIVATE LIMITED

Website

https://virchowbiotech.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Virchow Biotech is an India-based biopharmaceutical manufacturer that develops and commercializes biogenerics, biosimilars, APIs, and medical devices across 15+ therapeutic areas, serving pharmaceutical distributors, hospitals, and contract manufacturing clients in over 100 countries from its Hyderabad manufacturing base.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Biopharmaceutical products
• Biogenerics manufacturing
• Contract manufacturing services
• Wound care therapeutics
• Active pharmaceutical ingredients

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Biopharmaceutical Products: Revenue from sale of biogenerics, biosimilars, active pharmaceutical ingredients (APIs), medical devices, and finished dosage formulations across therapeutic areas including wound care, orthopedics, oncology, hematology, and gastroenterology
2. Contract Manufacturing Services: Third party manufacturing services providing formulation, tablet, injection and new drug manufacturing for clients. Project governance for loan licensing and CMO services with quality planning tools and real-time KPI monitoring
3. Co-development of Products: Co-development of products for various markets and customers around the world in partnership arrangements

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Virchow Biotech Private Limited (VBPL) develops, manufactures, and commercializes a portfolio of biogenerics, biosimilars, active pharmaceutical ingredients (APIs), medical devices, and finished dosage formulations across therapeutic areas including advanced wound care, orthopedics, oncology, hematology, gastroenterology, cardiology, ophthalmology, neurology, and critical care. The company also offers contract manufacturing services for tablets, injections, and new drugs, as well as R&D and co-development partnerships for global pharmaceutical clients.

Product overview

Virchow Biotech Private Limited (VBPL) is a biopharmaceutical company that develops and manufactures a diverse portfolio of biogenerics, pharmaceuticals, medical devices, and active pharmaceutical ingredients (APIs). The company's product portfolio is organized across multiple therapeutic categories including Advanced Wound Care (HEALACE, BIOZEL, SILVASORB, SCARAZE, DONASORB), Orthopedics (OSTEOTIDE, HYORTH), Hematology, Gastroenterology/Probiotics (ClasiPro, VI-PEG), Oncology (Rasburicase, Plerixafor), Cardiovascular (Fondaparinux, Enoxaparin), Vitamin Deficiency (Virinux, Voxaparin), Ophthalmology (HYOPT), Critical Care (Ulinastatin), Neurology (Sumatriptan), Endocrinology, Aesthetic Surgery (Hyfil), Equine Blood Products (VI-ASV), Nutraceuticals, OTC & Dietary Supplements, and Institutional Supplies. The company also offers Contract Manufacturing Services and Research & Development Services. VBPL is notable as the first company to commercialize Biogenerics of Recombinant Platelet Derived Growth Factor (rhPDGF) for wound healing and Recombinant PTH for treating Osteoporosis. The company operates across multiple manufacturing units in Hyderabad and serves clients in over 100 countries globally.

Differentiator

Problem solved

Functional benefit

Brands

• HEALACE: rh-Platelet Derived Growth Factor-BB Gel 0.01% – Bio-generic for wound healing treatment of Diabetic Neuropathic Foot Ulcers.
• BIOZEL
• IONSIL
• SCARAZE
• SILVASORB
• DEBRIDACE
• DONASORB
• OSTEOTIDE
• HYORTH XL
• HYORTH
• V-Immune
• V-Alb
• ClasiPro
• VI-PEG
• Virinux
• Hyfil

Products and services

• HEALACE (rh-Platelet Derived Growth Factor-BB Gel 0.01%) Bio-generic of the only US FDA approved growth factor in the world for treatment and management of Diabetic Neuropathic Foot Ulcers.
• BIOZEL (Sodium Hyaluronate Cream 0.2%) Sustained release ionic silver cream providing long term and broad spectrum antimicrobial action in burns and infected wounds.
• IONSIL (Ionic Silver Nitrate Gel 0.2%) Ionic silver nitrate gel for antimicrobial wound care in burns and infected wounds, available in various packaging sizes.
• SCARAZE (Cepae Extract, Heparin Sodium and Allantoin Gel) Gel that minimises hypertrophic and keloidal scars, movement-restricting and cosmetically disfiguring scars after operations, amputations, burns and accidents.
• SILVASORB (Silver Antimicrobial Wound Gel) Silver antimicrobial wound gel used to treat pressure injuries, leg ulcers, diabetic foot ulcers, graft wounds, surgical wounds and abrasions.
• DEBRIDACE (Papain-Urea Debriding Ointment) Painless, bloodless enzymatic therapy for debridement of slough and necrotic tissue in chronic ulcers.
• DONASORB (Silver Wound Dressing) Antimicrobial primary wound dressing for chronic wounds that absorbs exudate or donates moisture to maintain an ideal moist wound environment.
• Cadexomer Iodine Gel Gel for chronic exuding wounds including leg ulcers, pressure ulcers, diabetic ulcers, infected traumatic and surgical wounds.
• Nano Crystalline Silver Gel 0.002% Gel for management of first and second degree burns, pressure ulcers, venous stasis ulcers, diabetic ulcers, abrasions, lacerations, skin tears, grafted wounds, donor sites and surgical wounds.
• OSTEOTIDE (Teriparatide Injection 750µg/3mL) Bio-generic of the only US FDA approved bone forming agent used in osteopenic and osteoporotic patients.
• HYORTH XL (Cross-linked Hyaluronic Acid Gel Injection 8mg/mL) Viscosupplement injected once per year into an osteoarthritic knee to replace lost synovial fluid, providing lubrication and reducing pain.
• HYORTH (Hyaluronic Acid Gel Injection 10mg/mL) Viscosupplement injected into an osteoarthritic knee to replace lost synovial fluid, providing lubrication and reducing pain.
• V-Immune (Human Normal Immunoglobulin 5%) Human normal immunoglobulin especially useful during primary immunodeficiency states when high levels or rapid elevation of circulating antibodies are desired.
• V-Alb (Human Serum Albumin 5% and 20%) Human serum albumin for emergency treatment of conditions where restoration of blood volume is urgent.
• ClasiPro (Bacillus clausii spores suspension) Naturally found bacteria used in the management of diarrhea and prevention of infectious gastrointestinal diseases.
• VI-PEG (PEG Interferon Alpha 2b) Lyophilised powder for injection used in the treatment and management of Chronic Hepatitis C and Hepatitis B infections.
• Sofosbuvir Antiviral medication for HCV genotype 1, 2, 3 or 4 infection treatment.
• Rasburicase Lyophilized powder for management of Tumor Lysis Syndrome.
• Plerixafor Hematopoietic stem cell mobilizer indicated in combination with G-CSF to mobilize HSCs for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
• Peg L-Asparaginase Treatment for patients with Acute lymphoblastic leukemia.
• Fondaparinux (Virinux) Anticoagulant for Acute Pulmonary Embolism (PE) and Acute Coronary Syndrome, available as prefilled syringe.
• Enoxaparin (Voxaparin) Anticoagulant for Deep Vein Thrombosis or Acute Myocardial Infarction (STEMI), available as prefilled syringe, cartridges, and auto injector.
• HYOPT PLUS (Sodium Hyaluronate Injection 1.4%) Ophthalmic Viscosurgical Device (OVD) with viscoelastic properties used as a surgical aid in anterior segment ophthalmic surgical procedures.
• HYOPT (Sodium Hyaluronate Injection 1%) Sodium hyaluronate injection for ophthalmic surgical procedures.
• Hyfil (Cross-linked Hyaluronic Acid Gel Injection 20mg/mL) Hyaluronic acid dermal filler for smoothing away wrinkles and fine lines, creating fuller lips, and adding lift and volume to cheeks.
• VI-ASV (Snake Venom Antiserum) Antidote for snake venom, available as lyophilized powder for injection.
• Rabies Antiserum Antiserum providing immediate availability of neutralizing antibodies for rabies treatment.
• Iron (III) Isomaltoside 1000 Solution Treatment of iron deficiency, available as solution for infusion.
• Ulinastatin Critical care medication for severe sepsis treatment.
• Sumatriptan Succinate Treatment of acute migraine, available as auto injector.
• Parathyroid Hormone / Teriparatide / RhPTH 1-34
• Astaxanthin Soft Gel Capsules Nutraceutical that improves immune system function.
• Coenzyme Q10 Soft Gel Capsules Nutraceutical that balances healthy cholesterol levels.
• Curcumin Oil Soft Gel Capsules Nutraceutical for management of oxidative and inflammatory conditions.
• Fish Oil Soft Gel Capsules Nutraceutical that reduces inflammation, lowers triglycerides, and improves skin health.
• Contract Manufacturing Services Third party manufacturing services for tablets, injections, and new drugs that are DCGI approved, including project governance for loan licensing, quality planning tools, and risk assessment driven procedures for pharmaceutical clients.
• Research & Development Services R&D services focused on developing biological therapeutics, recombinant therapeutics, monoclonal antibodies, plasma derived products, and small molecules, with nearly 10% of company turnover invested in strengthening research.

Quantifiable outcome

• 24+ years of operational experience in biopharmaceuticals
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Biocon Limited: India-based biopharmaceutical company focused on biosimilars, biologics and active pharmaceutical ingredients with global commercial reach. Directly comparable to Virchow on biologics manufacturing, biosimilars pipeline, and exports to regulated and emerging markets.
• Dr. Reddy's Laboratories: Indian multinational that manufactures and markets generics, biosimilars and APIs across multiple therapeutic areas with strong global distribution. Overlaps with Virchow on finished dosage manufacturing, API production, and USFDA-certified export capabilities.
• Bharat Biotech: Hyderabad-based biopharma specializing in vaccines and biologics with global regulatory approvals. Comparable to Virchow's biologics manufacturing footprint, Hyderabad location, and stated vaccine development ambitions.
• Intas Pharmaceuticals: Indian generics and biosimilars manufacturer with international commercial infrastructure in biologics. Comparable to Virchow's biologics manufacturing, biosimilars focus, and overseas distribution capabilities across 100+ markets.
• Aurobindo Pharma: Large Indian pharmaceutical manufacturer with APIs, formulations, and biosimilars marketed globally. Overlaps with Virchow's API manufacturing, finished dosage production, and USFDA/WHO-GMP regulated exports.
• Reliance Life Sciences: Indian manufacturer of plasma-derived products, biosimilars and recombinant therapeutics for domestic and international markets. Highly comparable on the plasma-derived immunoglobulins and biologics portfolio that Virchow produces.
• Zydus Lifesciences (Cadila): Indian pharma group with biosimilars, vaccines, and a global manufacturing footprint spanning multiple regulatory jurisdictions. Comparable to Virchow's branded generics and biologics pipeline across regulated and emerging markets.

Broad incumbents

• Syngene International: Indian contract development and manufacturing organization serving global biopharma clients with biologics CDMO services. Comparable to Virchow's contract manufacturing services and biologics manufacturing infrastructure, though Syngene operates purely as a CRO/CDMO at larger scale.
• Serum Institute of India: World's largest vaccine manufacturer with strong plasma-derived product presence and global immunization supply contracts. Adjacent competitor to Virchow in biologicals and equine/plasma-derived antisera, with substantially larger scale and public health reach.

Regional players

• Shantha Biotechnics (Sanofi): Hyderabad-headquartered subsidiary of Sanofi focused on vaccines and biologics for global health markets. Comparable biologics capability to Virchow, though now operating as part of a multinational rather than an independent Indian player.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xinstagram.com/virchowbiotech?igsh=dmlhYjViZmkzbzZ2&utm_source=qr
• LinkedInlinkedin.com/company/virchowbiotech
• Instagraminstagram.com/virchowbiotech?igsh=dmlhYjViZmkzbzZ2&utm_source=qr
• Facebookfacebook.com/adminvirchow

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virchow Biotech